Pre-made Tezepelumab benchmark antibody ( Whole mAb, anti-TSLP therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tezepelumab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tezepelumab (INN; development codes MEDI9929 and AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis. It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-567-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Tezepelumab biosimilar, Whole Mab: Anti-TSLP therapeutic antibody
INN Name	Tezepelumab
Target	TSLP
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	5j13:CB
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Amgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia
Conditions Approved	na
Conditions Active	Asthma;Atopic dermatitis;Rhinosinusitis;Chronic obstructive pulmonary disease
Conditions Discontinued	na
Development Tech	na